Author Affiliations: Divisions of Adolescent Medicine (Dr Kahn) and Infectious Diseases (Dr Bernstein), Department of Pediatrics (Drs Kahn and Bernstein), Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine, Cincinnati, Ohio.
Cervical cancer is the second most common cancer among women globally, according to age-standardized incidence rates.1 Approximately 530 000 women are diagnosed with cervical cancer and 275 000 die of the disease every year; 88% of deaths occur in developing regions of the world.1 Human papillomavirus (HPV) infection is a well-established cause of cervical cancer as well as other anogenital and oropharyngeal cancers; therefore, prophylactic HPV vaccines have the potential to substantially reduce the incidence of cervical cancer and other HPV-associated diseases.2 Three-dose schedules of the bivalent vaccine (HPV-16 and -18) and the quadrivalent vaccine (HPV-6, -11, -16, and -18) have been shown to be highly efficacious in preventing persistent infection with HPV-16 and -18, which cause approximately 70% of cervical cancers, as well as precancerous lesions associated with these types.3- 5 The quadrivalent vaccine has also been shown to prevent anogenital warts associated with HPV-6 and -11.3,5
Kahn JA, Bernstein DI. HPV VaccinationToo Soon for 2 Doses?. JAMA. 2013;309(17):1832–1834. doi:10.1001/jama.2013.4147
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.